Journalism of Courage

Pres. Buhari re-appoints Prof. Adeyeye as NAFDAC DG for another 5-year term

Her re-appointment by President Muhammadu Buhari was announced on the verified Twitter of NAFDAC, Persecondnews reports.

Prof. Mojisola Christianah Adeyeye has been reappointed the Director-General, the National Agency for Food and Drug Administration and Control (NAFDAC).

Her re-appointment by President Muhammadu Buhari was announced on the verified Twitter of NAFDAC, Persecondnews reports.

It is for a final second term of five years.

Adeyeye, who reportedly stopped over at the agency’s headquarters in Abuja, held a brief meeting with some Directors on Friday.

The agency wrote on its twitter handle: “Prof. Mojisola Christianah Adeyeye has been reappointed as the Director-General, National Agency for Food and Drug Administration and Control (NAFDAC).

“She stopped by briefly at the corporate headquarters in Abuja to meet with some Directors.”

Adeyeye, a pharmacist-professor was first appointed the Director-General of NAFDAC on November 3, 2017 by Buhari.

Before her appointment as NAFDAC boss, she was the founding Chair of Biopharmaceutical Sciences and a Professor of Pharmaceutics, Manufacturing Science and Drug Product Evaluation at the College of Pharmacy, Roosevelt University in Schaumburg, Illinois, where she spent 7 years.

She was also a Professor of Pharmaceutics and Manufacturing for 21 years at Duquesne University in Pittsburgh, Pennsylvania, USA.

She is Senior Fulbright Scholar and Specialist and 2008 American Association of Pharmaceutical Scientists Fellow (the first African woman fellow).

She is also a Fellow of the Nigerian Academy of Science and Nigeria Academy of Pharmacy.

Her research interests are in the areas of pre-formulation, early phase development of solid, semisolid and liquid dosage forms, and IND-based and intellectual property-driven late phase drug product development.

She is the founder and President of Elim Pediatric Pharmaceuticals Rolling Meadows, Illinois.

Through Duquesne University, she was able to develop an anti-retroviral (HIV/AIDS) pediatric fixed-dose combination and received intellectual property on the formulations in the UK and South Africa.

 

Advertisement

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More